- Partial seizures:
- Adjunct treatment:
- Adult: PO 300mg BD increased by up to 600mg/day weekly. Max: 2400mg/day
- Adjunct treatment:
-
-
- 2-4 years: Initially PO 8-10mg/kg/day divided BD. Max 600mg/day
- <20 kg: May consider starting with 16-20mg/kg/day. May titrate to higher dose over 2-4 weeks. Max 60mg/kg/day
- 2-4 years: Initially PO 8-10mg/kg/day divided BD. Max 600mg/day
-
-
-
- 4-6 years: Initially PO 8-10mg/kg/day divided BD. Max 600mg/day
- 20-29kg: PO 450mg BD
- 1-39kg: PO 600mg BD
- >39 kg: PO 900mg BD
- 4-6 years: Initially PO 8-10mg/kg/day divided BD. Max 600mg/day
-
-
- Converting to monotherapy:
- Adult: PO 300mg BD, increased by up to 600mg/day weekly. Max: 2400mg/day
- Reduce and withdraw concomitant antiepileptic drugs (AEDs) over 3-6 weeks while reaching maximum oxcarbazepine dose in 2-4 weeks
- Converting to monotherapy:
-
-
- 4-16 years: Initially PO 8-10mg/kg/day divided BD, while simultaneously reducing concomitant AEDs dose(s) over 3-6 weeks
- 20-24.99kg: 600-900mg/day
- 25-34.99kg: 900-1200mg/day
- 35-44.99kg: 900-1500mg/day
- 45-49.99kg: 1200-1500mg/day
- 50-59.99kg: 1200-1800mg/day
- 60-69.99kg: 1200-2100mg/day
- 70kg: 1500-2100mg/day
- 4-16 years: Initially PO 8-10mg/kg/day divided BD, while simultaneously reducing concomitant AEDs dose(s) over 3-6 weeks
-
-
- Initial monotherapy: PO 300mg BD, increased by 300mg/day every 3 days
- Trigerminal neuralgia (Off-label):
- PO 300mg BD, may increase by 600mg/day weekly
- Dose range: 450-1200mg BD
- Bipolar disorder (Off-label):
- Initially PO 300mg/day and increased by 300mg/day every 3 days or by 600mg/day every week
- Dose range: 600-1200mg BD
- May titrate to 1800-2400mg/day maximum
- Diabetic neuropathy (Off-label):
- PO 150-300mg/day initially increased to 900-1200mg/day
- Tablet:
- 300mg
- 600mg
- Suspension:
- 60mg/mL
- Mix drawn suspension in a small glass of water just prior to administration or may be swallowed directly from the syringe
- To be taken with/without food
Anticonvulsant
It blocks voltage-sensitive Na channels, stabilizes neural membranes, inhibits repetitive firing and decreases synaptic impulse propagation
- Dizziness
- Headache
- Nausea
- Vomiting
- Somnolence
- Diplopia
- Balance disorder
- Fatigue
- Asthenia
- Tremor
- Hyponatremia
- Visual disturbance
- Nystagmus
- Ataxia
- Abnormal gait
- Abdominal pain
- Dyspepsia
- Gastritis
- Diarrhea
- Constipation
- Cognitive dysfunction
- Impaired concentration
- Confusion
- URI symptoms
- Rash
- Nervousness
- Insomnia
- Acne
- Photosensitivity
- Hypersensitivity to eslicarbazepine acetate
- HLA-B*1502 allele (treatment-naive patients)
- Abrupt withdrawal
- Artemether/lumefantrine
- Cariprazine
- Cobimetinib
- Dienogest/estradiol valerate
- Doravirine
- Elbasvir/grazoprevir
- Elvitegravir/cobicistat/emtricitabine/tenofovir df
- Eslicarbazepine acetate
- Ledipasvir/sofosbuvir
- Lumacaftor/ivacaftor
- Lumefantrine
- Lurasidone
- Naloxegol
- Ombitasvir/paritaprevir/ritonavir & dasabuvir (dsc)
- Panobinostat
- Praziquantel
- Regorafenib
- Rilpivirine
- Roflumilast
- Vandetanib
Drug Status
Availability | Prescription only |
Pregnancy | Category C |
Breastfeeding | Weigh risk vs benefit |
Schedule | Controlled |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Trileptal | 300mg | Tablet | 50’s | Novartis Pharma | Novartis Kenya |
Trileptal | 600mg | Tablet | 50’s | Novartis Pharma | Novartis Kenya |
Trileptal | 60mg/mL | Suspension | 100mL | Novartis Pharma | Novartis Kenya |